Our History of Advancing Science
Established in 2003 by world-renowned researchers, our history is deeply rooted in science and our research and development efforts are focused on disease areas with significant unmet need for new treatment options to help improve the lives of patients.
Menarini Group and Radius Health announced positive Phase 3 topline results from the EMERALD trial evaluating elacestrant in breast cancer.
Radius announced positive Phase 3 topline results for the ATOM trial evaluating abaloparatide subcutaneous injection in males with osteoporosis.
Radius Health announced plans for a global Prader-Willi Syndrome pivotal study.
Radius Health announced $175 million financing transaction.
Radius announced the acquisition of the global development and commercialization rights to RAD011, a synthetic cannabidiol oral solution, from Benuvia Therapeutics Inc.
Radius successfully sells its second oncology pipeline asset – RAD140 – to Ellipses Pharma Limited, completing Radius’ divestment of its oncology assets.
The EMERALD Phase 3 Study, which is evaluating the efficacy and safety of elacestrant in postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer, achieved its targeted recruitment of 466 patients.
The wearABLe Phase 3 Study, which is evaluating the efficacy and safety of abaloparatide-TD in post-menopausal women with osteoporosis, achieved its targeted recruitment of 474 patients.
The ATOM Phase 3 Study, which is assessing the efficacy and safety of abaloparatide-SC in men with osteoporosis, achieved its targeted recruitment of 225 patients.
Radius and the Menarini Group entered into an exclusive global license agreement for the development and commercialization of elacestrant.
Kelly Martin appointed President and Chief Executive Officer.
Radius initiated the Phase 3 wearABLe study to evaluate the efficacy and safety of abaloparatide-TD for the treatment of postmenopausal women with osteoporosis.
Radius initiated its Phase 3 EMERALD study, a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in advanced/metastatic ER-positive (ER+)/HER2-negative (HER2-) breast cancer patients.
Radius initiated the Phase 3 ATOM (Abaloparatide Treatment for Osteoporosis in Males) study of abaloparatide injection for the treatment of osteoporosis in men.
Radius announced scale-up and commercial supply agreement with 3M to exclusively manufacture commercial supplies of abaloparatide-TD.
Radius provided update on data from the clinical studies of elacestrant during the 2017 San Antonio Breast Cancer Symposium (SABCS).
U.S. Food and Drug Administration granted Fast Track designation for elacestrant.
Radius initiated Phase 1 study of RAD140, an internally developed selective androgen receptor modulator (SARM) undergoing clinical evaluation for the treatment of hormone receptor positive breast cancer.
Radius presented update on data from ongoing study of elacestrant at the American Society of Clinical Oncology (ASCO) Meeting.
TYMLOS® (abaloparatide) injection was approved on April 28, 2017 by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Please see: Full Prescribing Information
Radius presented data from two ongoing Phase 1 studies of elacestrant in patients with estrogen receptor positive (ER+) breast cancer at the San Antonio Breast Cancer Symposium (SABCS).
Radius’ NDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis accepted for filing by the U.S. Food and Drug Administration.
Radius commenced a Phase 1 FES-PET study in patients with metastatic breast cancer in the European Union, which includes the use of FES-PET imaging to assess estrogen receptor occupancy in tumor lesions following elacestrant treatment.
Radius presented data from the first six months of ACTIVExtend trial during the American Society for Bone and Mineral Research (ASBMR) Annual Meeting.
Radius presented data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial during the Endocrine Society (ENDO) Annual Meeting.
Radius commenced elacestrant Phase 1 study in postmenopausal women with ER+ and HER2- advanced breast cancer in the United States.
Radius completed successful IPO.
Abaloparatide-SC Phase 3 extension study (ACTIVExtend) commenced.
Radius and 3M Drug Delivery Systems announced exclusive agreement for development of abaloparatide-TD.
Radius initiated Phase 2 Study of abaloparatide-TD for the Treatment of Postmenopausal Osteoporosis.
Abaloparatide-SC Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial initiated in postmenopausal women with osteoporosis.
Abaloparatide-SC Phase 2 trial initiated in postmenopausal women with osteoporosis.
Radius in-licensed elacestrant (RAD1901), a selective estrogen receptor degrader (SERD).
Nuvios became Radius Health, Inc.
Nuvios in-licensed abaloparatide.